19 completed. 19 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Meningococcal Meningitis: new trials by email Literature Review of Meningococcal Meningitis trials Research Report on Meningococcal Meningitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 224 | 2016-06-06 | 2018-01-08 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 188 | 2015-03-31 | 2022-04-04 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1715 | 2014-07-22 | 2022-04-04 |
| Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine Test Vaccine, US Licensed Vaccine - Meningococcal Meningitis, Meningococcal Infections | Phase 2 | Completed | JN-International Medical Corporation | 525 | 2013-07-01 | 2015-04-23 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 301 | 2012-11-12 | 2022-04-04 |
| Comparison of Two Meningococcal ACWY Conjugate Vaccines Menveo, MenACWY-TT - Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Public Health England | 91 | 2012-06-01 | 2020-10-01 |
| Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis | 992 | 2011-09-01 | 2017-04-25 |
| Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 440 | 2011-07-01 | 2014-11-19 |
| Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents Meningococcal Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 495 | 2010-12-01 | 2011-10-24 |
| Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi | 139 | 2010-11-01 | 2012-06-25 |
| Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Novartis Vaccines | 817 | 2010-08-01 | 2018-06-15 |
| A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY Novartis Meningococcal (MenACWY-CRM) vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 155 | 2010-01-01 | 2015-07-15 |
| Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants Meningococcal B vaccine, Control, Meningococcal B vaccine with antipyretic - Meningococcal Meningitis, Meningococcal Infections | Phase 2 | Completed | Novartis Vaccines | 1507 | 2009-07-01 | 2015-04-07 |
| Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 rMenB+OMV NZ with routine vaccinations, rMenB+OMV NZ, two doses of rMenB+OMV NZ - Meningococcal Disease, Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Novartis Vaccines | 1588 | 2009-07-01 | 2017-08-14 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 216 | 2007-10-01 | 2013-09-20 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningococcal Meningitis, Tetanus | Phase 2 | Completed | Sanofi | 882 | 2006-10-01 | 2011-08-24 |
| Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine Mencevax ACW Vaccine - Meningococcal Meningitis | Phase 2 | Completed | Armauer Hansen Research Institute, Ethiopia | 412 | 2005-11-01 | 2009-10-16 |
| Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) MenACWY-CRM, MenC-CRM, DTaP-Hib-IPV - Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 175 | 2005-06-01 | 2018-10-09 |
| Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY polysaccharide vaccine, MenACWY-CRM conjugate vaccine, unadjuvanted - Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 623 | 2005-03-01 | 2015-11-06 |
Meningitis, Meningococcal (19) · Meningococcal Infections (14) · Meningitis (13) · Central Nervous System Infections (1) · Diphtheria (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Bacterial Infections (19) · Bacterial Infections and Mycoses (19) · Central Nervous System Bacterial Infections (19) · Central Nervous System Diseases (19) · Gram-Negative Bacterial Infections (19) · Infections (19) · Meningitis, Bacterial (19) · Neisseriaceae Infections (19) · Nervous System Diseases (19) · Neuroinflammatory Diseases (19) · Central Nervous System Infections (18) · Meningitis (6) · Meningococcal Infections (5) · Actinomycetales Infections (1) · Bordetella Infections (1)
Meningococcal Vaccines (8) · Vaccines (2) · 4CMenB vaccine (1) · Antipyretics (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · MenACWY-CRM vaccine (1) · MenC-CRM vaccine (1) · Papillomavirus Vaccines (1) · Tetanus Toxoid (1) · adacel (1) · diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (1) · pentacel (1)
Novartis Vaccines (8) · Sanofi Pasteur, a Sanofi Company (5) · Sanofi (2) · Armauer Hansen Research Institute, Ethiopia (1) · JN-International Medical Corporation (1) · Novartis (1) · Public Health England (1)
United States (7) · Chile (4) · Colombia (2) · Czechia (2) · Finland (2) · Italy (2) · Panama (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Canada (1) · Ethiopia (1) · Germany (1) · Hungary (1)
Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Alberto Yataco, MD (1) · Elizabeth Miller, MD (1) · Francisco Diaz-Mitoma, Dr. (1) · Jeffrey E Atkinson, MD (1) · Myron I Murdock, MD (1) · Scott Halperin, Dr. (1)
PMID 17548138, PMID 21177912, PMID 23114372, PMID 25424810, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26756390, PMID 32209248, PMID 32233959, PMID 32233961, PMID 33020485, PMID 35257644
2009 (2), 2014 (1)